By signing the Copyright Letter the authors retain the rights of self-archiving. Following are the important features of self-archiving policy of Bentham Science journals:
Authors can deposit the first draft of a submitted article on their personal websites, their institution’s repositories or any non-commercial repository for personal use, internal institutional use or for permitted scholarly posting.
Authors may deposit the ACCEPTED VERSION of the peer-reviewed article on their personal websites, their institution’s repository or any non-commercial repository such as PMC, arXiv after 12 MONTHS of publication on the journal website. In addition, an acknowledgement must be given to the original source of publication and a link should be inserted to the published article on the journal's/publisher’s website.
If the research is funded by NIH, Wellcome Trust or any other Open Access Mandate, authors are allowed the archiving of published version of manuscripts in an institutional repository after the mandatory embargo period. Authors should first contact the Editorial Office of the journal for information about depositing a copy of the manuscript to a repository. Consistent with the copyright agreement, Bentham Science does not allow archiving of FINAL PUBLISHED VERSION of manuscripts.
The link to the original source of publication should be provided by inserting the DOI number of the article in the following sentence: “The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/openurl/content.php?genre=article&doi=[insert DOI].”
There is no embargo on the archiving of articles published under the OPEN ACCESS PLUS category. Authors are allowed deposition of such articles on institutional, non-commercial repositories and personal websites immediately after publication on the journal website.
Prof. Debomoy K. Lahiri (15455 citations) Neuroscience Research Center Indianapolis, IN 46202 USA
Dr. Debomoy Lahiri is Professor at Indiana University School of Medicine, USA. His major research focus is to understand the mechanism of aging, origin and biogenesis of the amyloid plaque, and to discover drug targets for Alzheimer's disease (AD) and other brain disorders. Dr. Lahiri’s group has shown the novel role of specific microRNA species in regulation of genes implicated in AD as well as the role of gene and environment interaction in late-life disorders. Also, his team has made significant contributions to understanding the biochemical pathway for neurodevelopment disorders, such as autism and fragile X syndrome. Dr. Lahiri is the Editor-In-Chief of the international journal, ‘Current Alzheimer Research' (Bentham). He authored books, such as ‘Protective Strategies for Neurodegenerative Diseases' published by the New York Academy of Sciences. Dr. Lahiri was awarded grants as a Principal Investigator from the National Institute on Aging, NIH, and Alzheimer’s Association, USA. His other honors include the ‘Zenith Award’ and listing in Marquis' ‘Who's Who in the World'.